Andrew Kruse

Andrew is Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and a co-Founder of Tectonic. His research focuses on the molecular basis of membrane protein signaling and the study of proteins important in human health and disease. Andrew was selected for the 2016 Forbes “30 under 30” list and is the recipient of a Smith Family Award for Excellence in Biomedical Research, a Klingenstein-Simons Fellowship, and an NIH Director’s Early Independence Award. He is also a 2016 Vallee Scholar, an Amgen Young Investigator and the recipient of a 2017 Sloan Research Fellowship. Andrew completed his Ph.D. in Molecular and Cellular Physiology and Medicine at Stanford University in the laboratory of Prof. Brian Kobilka.